News

AZ and Innate in €1.2bn immuno-oncology deal
Enlarge image

PoliticsFranceUKSweden

AZ and Innate in €1.2bn immuno-oncology deal

24.04.2015 - AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

Under the terms of the co-development and commercialisation agreement, the Marseille-based biotech will receive cash payments of up to US$1.275bn (€1.17bn) as well as double digit royalties on sales. AstraZeneca and its biologics R&D arm Medimmune gain exclusive global rights to co-develop and commercialise IPH2201 in combination with MEDI473, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. The Swedish-British pharma giant also gains access to IPH2201 in monotherapy and other combinations in certain areas.

In addition to an initial payment of US$250m (€230m), AstraZeneca will grant further regulatory and sales-related milestones of up to US$925m (€851m). AstraZeneca will book all sales and will pay Innate double-digit royalties on net sales. Innate retains the right to co-promote in Europe with a 50% profit share in the territory.

Currently in Phase II development, IPH2201 is a potential first-in-class humanised anti-NKG2A antibody. The checkpoint receptor NKG2A inhibits the anti-cancer functions of Natural Killer (NK) and cytotoxic cells.

© european-biotechnology-news.com/jc

http://www.european-biotechnology-news.com/news/news/2015-02/az-and-innate-in-eur12bn-immuno-oncology-deal.html

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Stock MarketsFrance

02.04.2015 Sensorion is the latest French biotech to go public, following a spate of IPOs on Paris Euronext. The biopharma plans for a €12m IPO to finance its pipeline of inner ear disease drugs.

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/news/news/pos/1.html

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%

FLOP

  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%

TOP

  • CO.DON3.15 EUR22.1%
  • WILEX3.59 EUR21.3%
  • FORMYCON28.00 EUR21.0%

FLOP

  • CYTOS1.01 CHF-27.9%
  • BIOTEST79.20 EUR-18.1%
  • THERAMETRICS0.07 CHF-12.5%

TOP

  • SANTHERA98.85 CHF2460.9%
  • CYTOS1.01 CHF676.9%
  • WILEX3.59 EUR337.8%

FLOP

  • MOLOGEN5.07 EUR-54.8%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.41 EUR-28.1%

No liability assumed, Date: 25.04.2015